Data Sheet (Cat.No.T28414)

TargetMol

Piclozotan

Chemical Properties



CAS No. : 182415-09-4

Formula: C23H24ClN3O2

Molecular Weight: 409.91

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Piclozotan (anhydrous), a 5-HT1A receptor agonist, demonstrated significant neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model, ameliorating motor complications in patients with advanced Parkinson's disease.
Targets(IC50)	5-HT Receptor
In vivo	Piclozotan (SUN N4057) (0.018 and 0.036 mg/kg/h; continuous subcutaneous infusion; 3 to 4 weeks; Parkinsonian rats) significantly lengthened the duration of rotational behavior by 26% and attenuated the increase in striatal levodopa-derived extracellular dopamine levels compared with the control group. Piclozotan (0.018 and 0.036 mg/kg/h, plasma concentrations 5.3±0.7 and 14.3±2.9 ng/ml) reduced levodopa-induced forelimb hyperkinesia by 55% and 69%, respectively, at 1h relative to the control.[1]

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4396 mL	12.1978 mL	24.3956 mL
5 mM	0.4879 mL	2.4396 mL	4.8791 mL
10 mM	0.244 mL	1.2198 mL	2.4396 mL
50 mM	0.0488 mL	0.244 mL	0.4879 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Tani Y, et al Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats. Eur J Pharmacol. 2010;649(1-3):218-223.
Mondick JT, et al. Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan. Am J Ther. 2009;16(2):106-115.
Kamei K, et al. Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan. Bioorg Med Chem. 2006;14(6):1978-1992.
Ferro JM, et al. Other neuroprotective therapies on trial in acute stroke. Cerebrovasc Dis. 2006;21 Suppl 2:127-130.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481